Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab
2006; Oxford University Press; Volume: 45; Issue: 11 Linguagem: Inglês
10.1093/rheumatology/kel098
ISSN1462-0332
AutoresRoberto Stasi, Elisa Stipa, Giovanni Del Poeta, Sergio Amadori, Adrian C. Newland, Drew Provan,
Tópico(s)Neutrophil, Myeloperoxidase and Oxidative Mechanisms
ResumoObjective. Rituximab, a chimeric anti-CD20 monoclonal antibody, has been shown to be quite effective in the treatment of immune disorders resulting from autoantibodies. We prospectively studied the long-term effects of rituximab in 10 patients with anti-neutrophil cytoplasmic antibody (ANCA)-positive vasculitis refractory to conventional therapy (n=3) or in second or subsequent relapse (n=7).
Referência(s)